title: Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.
abstract: OBJECTIVE
  Adiponectin is a polypeptide hormone produced by adipocytes that has anti-angiogenic properties. Circulating adiponectin is lower in obese men. Obesity has been associated with advanced stage and a higher risk of biochemical progression following radical prostatectomy (RP) in several series. We examined whether serum adiponectin is associated with advanced disease stage at RP.
  
  
  METHODS
  Adiponectin was measured by enzyme-linked immunosorbent assay in the preoperative serum of 236 men treated with RP between 1998 and 1999. The odds ratio (OR) of advanced stage (pT3a or greater) and high grade disease (pathological Gleason sum 7 or greater) associated with quartiles of adiponectin were estimated using multivariate logistic regression models.
  
  
  RESULTS
  Serum adiponectin weakly correlated inversely with body mass index (Spearman r = -0.22, p = 0.01). Serum adiponectin was not associated with cancer stage or grade. However, in normal weight men adiponectin was positively associated with high stage disease (OR 1.14, 95% CI 1.02 to 1.29, p = 0.03), although there was no statistically significant association with high grade disease (OR 1.05, 95% CI 0.94 to 1.18, p = 0.38). In overweight and obese men adiponectin was inversely associated with high grade disease (OR 0.94, 95% CI 0.87 to 1.01, p = 0.09), although there was no statistically significant association with high stage disease (OR 0.97, 95% CI 0.91 to 1.04, p = 0.43). Further adjustments for body mass index had little impact on any ORs.
  
  
  CONCLUSIONS
  These data provide evidence to suggest that adiponectin may be related to prostate cancer aggressiveness, although the direction of the associations may depend on the extent of adiposity and on cancer grade.
authors.affiliation: The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA. sfreedl1@jhmi.edu
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Sokoll
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Platz
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Mangold
authors.forename: Debra J
authors.initials: DJ
authors.lastname: Bruzek
authors.forename: Phaedre
authors.initials: P
authors.lastname: Mohr
authors.forename: Sindy K
authors.initials: SK
authors.lastname: Yiu
authors.forename: Alan W
authors.initials: AW
authors.lastname: Partin
mesh_terms: D052242:Adiponectin; D015992:Body Mass Index; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D020738:Leptin / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery
chemical_list: D052242:Adiponectin; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D017430:Prostate-Specific Antigen